How 48 Import Referrals Led to BPC-157 Becoming Schedule 4 in Australia
48 Referrals Since July 2022
The TGA received 48 referrals for importation of BPC-157 since 1 July 2022, according to the delegate's published reasons for the scheduling decision.
This referral count was the practical trigger for the review. Each referral represents a case where the substance was flagged at the border or through an import pathway, prompting regulatory attention to a peptide that had not previously been scheduled.
BPC-157 is a synthetic peptide that has circulated in research and bodybuilding circles for some years. Most peptides sold or supplied in Australia are prescription-only medicines, and this scheduling decision brought BPC-157 formally into that category.
The November 2023 Poisons Standard Amendment
The final decision was published alongside the November 2023 amendments to the Poisons Standard, the document that governs how substances are classified for legal supply and possession in Australia.
This amendment created a new Schedule 4 entry for BPC-157, placing it in the same regulatory category as other prescription-only substances. It also added an Appendix D clause 5 entry, which makes possession of the substance without lawful authority a separate offence.
The dual listing matters. Schedule 4 status controls supply and prescribing, while the Appendix D clause addresses individuals who might otherwise possess the substance outside a medical or pharmacy channel.
What the Advisory Committee Recorded
The committee voted to support scheduling after recording specific concerns in its published reasons. It noted a lack of clinical data on both the short- and long-term effects of BPC-157 in humans.
The TGA states that toxicity for BPC-157 has not been adequately characterised, meaning regulators lack the safety data typically expected before a substance is left unregulated or lightly regulated.
The committee also recorded that BPC-157 sits on the World Anti-Doping Agency prohibited list. This placement on an international sporting prohibition list was cited as part of the evidence base for tightening domestic control, reflecting concern about non-clinical use patterns.
1 June 2024 and No Registered Products
The scheduling change took effect on 1 June 2024, the date from which BPC-157 has been treated as a Schedule 4 substance under Australian poisons law.
The TGA noted there were no registered products affected by the change. This detail is significant: no approved medicine containing BPC-157 existed on the Australian Register of Therapeutic Goods at the time, so the scheduling closed off unauthorised supply routes rather than altering the status of any approved treatment.
The absence of registered products also confirms that BPC-157 has not been approved by the TGA for any therapeutic use in Australia. Scheduling controls access and legal status; it does not, by itself, constitute approval or evidence of efficacy for any condition.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.